Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9841014 | 0.85 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL26988864 | 0.85 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL9841010 | 0.85 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL24464141 | 0.83 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL24514516 | 0.83 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL26290931 | 0.81 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL18510056 | 0.81 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL23673447 | 0.81 | MAOB (0.45) | ALDH1A1MAOBHPGDCTSB | |
| SCHEMBL7429091 | 0.81 | ALDH1A1 (0.60) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL10493728 | 0.81 | ALDH1A1 (0.60) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150431-A1 | MHC Multimers, Methods for Their Generation, Labeling and Use | DAKO DENMARK APS (DK) | 2024-05-09 | — | — | US | disclosed |
| EP-3898666-A2 | PANEL COMPRISING BORRELIA MHC MULTIMERS | Immudex ApS (DK) | 2021-10-27 | — | — | EP | disclosed |
| US-10968269-B1 | MHC multimers in borrelia diagnostics and disease | AGILENT TECHNOLOGIES, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210047383-A1 | MHC Multimers in Borrelia Diagnostics and Disease | DAKO DENMARK APS (DK) | 2021-02-18 | — | — | US | disclosed |
| US-20200347103-A1 | MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS | AGILENT TECHNOLOGIES INC (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200347114-A1 | MHC Peptide Complexes and Uses Thereof in Infectious Diseases | AGILENT TECHNOLOGIES, INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2020127222-A2 | PANEL COMPRISING BORRELIA MHC MULTIMERS | IMMUDEX APS (DK) | 2020-06-25 | — | — | WO | disclosed |
| US-10611818-B2 | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics | AGILENT TECHNOLOGIES, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| EP-3620465-A1 | IMPROVED METHODS FOR GENERATION, LABELING AND USE OF MHC MULTIMERS | Dako Denmark A/S (DK) | 2020-03-11 | — | — | EP | disclosed |
| US-10336808-B2 | MHC peptide complexes and uses thereof in infectious diseases | DAKO DENMARK A/S (DK) | 2019-07-02 | — | — | US | disclosed |
| WO-2010037395-A2 | MHC MULTIMERS IN CANCER VACCINES AND IMMUNE MONITORING | DAKO DENMARK A/S (DK) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010037397-A1 | MHC MULTIMERS IN CMV IMMUNE MONITORING | DAKO DENMARK A/S (DK) | 2010-04-08 | — | — | WO | disclosed |
| EP-2167536-A1 | MHC MULTIMERS, METHODS FOR THEIR GENERATION, LABELING AND USE | Dako Denmark A/S (DK) | 2010-03-31 | — | — | EP | disclosed |
| EP-2155782-A2 | MHC PEPTIDE COMPLEXES AND USES THEREOF IN INFECTIOUS DISEASES | Dako Denmark A/S (DK) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009106073-A2 | MHC MULTIMERS IN BORRELIA DIAGNOSTICS AND DISEASE | DAKO DENMARK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009039854-A2 | MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS | DAKO DENMARK A/S (DK) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009003492-A1 | MHC MULTIMERS, METHODS FOR THEIR GENERATION, LABELING AND USE | DAKO DENMARK A/S (DK) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008116468-A2 | MHC PEPTIDE COMPLEXES AND USES THEREOF IN INFECTIOUS DISEASES | DAKO DENMARK A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| EP-1907592-A2 | MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES | Dako Denmark A/S (DK) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007015168-A2 | MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES | DAKO DENMARK A/S (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150431-A1 | MHC Multimers, Methods for Their Generation, Labeling and Use | MICA, CD74, HLA-DRB1 | ALDH1A1 2776/4885MAOB 3666/4885MAPK1 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.